# Project 2 Skills Roadmap: Resistance-Resilient Polypharmacological Antimalarials

**Based on:** JCIM_COMPLIANT_ROADMAP.md v2.0  
**Target:** MD + Monte Carlo validation of Paper 1 candidates  
**Timeline:** May 2026 - March 2027  
**Systems:** 220 MD+MC systems (30,000 ns MD + 2,200,000 MC steps)

---

## Phase 1: Project Setup & Validation (May 2026)

### 1.1 Project Documentation & Planning

**`bmad-help`** - Get oriented and understand next steps
- Use when: Starting new phases or when unsure of next steps
- Context: "Where am I in the Project 2 workflow?"

**`bmad-document-project`** - Document the current project state
- Use for: Creating comprehensive project documentation
- Output: Project overview with current status and structure

**`bmad-create-prd`** - Create Product Requirements Document
- Use for: Formalizing Project 2 requirements and deliverables
- Focus: MD validation requirements, success metrics, JCIM compliance

### 1.2 Technical Research & Background

**`bmad-technical-research`** - Research MD simulation methodologies
- Topics: GROMACS protocols, Monte Carlo sampling, MM-GBSA calculations
- Output: Technical research reports on MD best practices

**`bmad-domain-research`** - Research resistance mutations and polypharmacology
- Topics: PfDHFR/PfCRT resistance mechanisms, African malaria epidemiology
- Output: Domain knowledge for mutation selection and validation

### 1.3 Architecture & System Design

**`bmad-create-architecture`** - Design MD simulation pipeline architecture
- Components: GROMACS workflow, OpenMM MC integration, analysis pipeline
- Output: Technical architecture for 220-system pipeline

**`bmad-create-ux-design`** - Design analysis workflows and visualization
- Focus: MD trajectory analysis, MC landscape visualization, results dashboard
- Output: UX specifications for analysis tools

---

## Phase 2: Development Planning (June 2026)

### 2.1 Epic & Story Creation

**`bmad-create-epics-and-stories`** - Break down MD pipeline into development tasks
- Epics: Protein preparation, ligand parameterization, MD setup, MC implementation
- Stories: Individual scripts and validation steps

**`bmad-sprint-planning`** - Plan development sprints for MD pipeline
- Focus: Prioritize critical path items (homology modeling → MD setup → production)
- Output: Sprint plans with dependencies and timelines

### 2.2 Code Development

**`bmad-quick-dev`** - Implement MD preparation scripts
- Tasks: Protein preparation, ligand parameterization, system setup
- Focus: Enhanced error handling and validation

**`bmad-dev-story`** - Develop specific MD pipeline components
- Use for: Individual script development with full context
- Examples: Homology modeling, force field assignment, trajectory analysis

### 2.3 Quality Assurance

**`bmad-code-review`** - Review MD simulation scripts
- Focus: Scientific accuracy, error handling, reproducibility
- Layers: Blind Hunter, Edge Case Hunter, Acceptance Auditor

**`bmad-qa-generate-e2e-tests`** - Create end-to-end tests for MD pipeline
- Tests: System preparation, simulation stability, analysis accuracy
- Coverage: All 220 system types and failure modes

---

## Phase 3: Resistance Mutation Modeling (June 2026)

### 3.1 Homology Modeling Skills

**`bmad-quick-dev`** - Enhance homology modeling scripts
- Target: `scripts/md/md_homology_mutants_refined.py`
- Features: SWISS-MODEL integration, quality validation, fallback methods

**`bmad-technical-research`** - Research resistance mutation mechanisms
- Mutations: PfDHFR (N51I, C59R, S108N, I164L), PfCRT (K76T, K76A)
- Output: Structural and functional impact analysis

### 3.2 Structure Validation

**`bmad-review-edge-case-hunter`** - Validate homology model quality
- Criteria: QMEAN > -4.0, GMQE > 0.7, Ramachandran > 95%, RMSD < 1.5 Å
- Edge cases: Low-quality models, missing residues, clashes

**`bmad-qa-generate-e2e-tests`** - Test homology modeling pipeline
- Tests: Structure quality, mutation validation, file format consistency
- Coverage: All 6 resistance mutations across different methods

---

## Phase 4: Novel Metrics Development (June 2026)

### 4.1 Metric Implementation

**`bmad-quick-dev`** - Implement novel scoring metrics
- RRS (Resistance Resilience Score): Activity retention against mutants
- ACSI (African Chemical Space Index): Chemical space positioning
- PNS (Polypharmacology Network Score): STRING PPI network-based scoring

**`bmad-technical-research`** - Research STRING PPI networks and centrality measures
- Focus: Protein interaction networks, centrality algorithms, malaria pathways
- Output: Technical foundation for PNS implementation

### 4.2 Validation & Testing

**`bmad-code-review`** - Review metric calculation algorithms
- Focus: Mathematical correctness, edge case handling, performance
- Validation: Cross-check with literature values and expected ranges

**`bmad-review-adversarial-general`** - Critical review of metric definitions
- Questions: Are metrics biologically meaningful? Do they correlate appropriately?
- Output: Refined metric definitions and validation criteria

---

## Phase 5: MD System Preparation (July 2026)

### 5.1 System Setup Development

**`bmad-quick-dev`** - Develop MD system preparation pipeline
- Components: Protein preparation, ligand parameterization, solvation, minimization
- Target: 220 systems (80 WT + 120 mutant + 20 controls)

**`bmad-create-story`** - Create detailed stories for each preparation step
- Stories: Force field assignment, box setup, ion placement, energy minimization
- Context: CHARMM36m + OpenFF 2.2 + TIP3P combination

### 5.2 Force Field Integration

**`bmad-technical-research`** - Research force field compatibility
- Focus: CHARMM36m/OpenFF integration, CGenFF parameterization, validation protocols
- Output: Force field selection and validation strategy

**`bmad-quick-dev`** - Implement enhanced ligand preparation
- Target: `scripts/md/md_prepare_ligands_refined.py`
- Features: Multiple force field support, validation, error recovery

---

## Phase 6: Monte Carlo Implementation (July-August 2026)

### 6.1 MC Algorithm Development

**`bmad-quick-dev`** - Implement OpenMM Monte Carlo sampling
- Algorithm: Metropolis MC with mixed move sets
- Moves: Translation (40%), rotation (30%), torsion (20%), side-chain (10%)
- Target: 10,000 steps per system, 100 snapshots saved

**`bmad-technical-research`** - Research MC sampling best practices
- Topics: Move acceptance rates, convergence criteria, binding landscape exploration
- Output: MC protocol optimization and validation methods

### 6.2 MC Integration & Testing

**`bmad-dev-story`** - Integrate MC with MD pipeline
- Integration: Start from final MD snapshot, run MC, analyze convergence
- Validation: |ΔG_MC - ΔG_MD| < 2 kcal/mol convergence criterion

**`bmad-qa-generate-e2e-tests`** - Test MC sampling pipeline
- Tests: Acceptance rate validation, convergence checking, pose clustering
- Coverage: All system types and edge cases

---

## Phase 7: Production Simulations (August-October 2026)

### 7.1 Workflow Orchestration

**`bmad-quick-dev`** - Develop production simulation orchestration
- Features: Batch submission, progress monitoring, failure recovery
- Scale: 220 systems across 4 A100 GPUs, ~45 days runtime

**`bmad-create-story`** - Create monitoring and logging systems
- Components: Progress tracking, resource utilization, error detection
- Output: Real-time simulation monitoring dashboard

### 7.2 Quality Control

**`bmad-qa-generate-e2e-tests`** - Implement simulation quality checks
- Checks: Stability criteria, convergence monitoring, file integrity
- Criteria: RMSD < 0.30 nm (backbone), < 0.25 nm (ligand), H-bond > 30%

**`bmad-review-edge-case-hunter`** - Identify simulation failure patterns
- Analysis: System instability causes, convergence issues, hardware failures
- Output: Failure classification and recovery strategies

---

## Phase 8: Analysis & Validation (November 2026)

### 8.1 Trajectory Analysis

**`bmad-quick-dev`** - Implement comprehensive trajectory analysis
- Metrics: RMSD, RMSF, Rg, SASA, H-bonds, DSSP secondary structure
- Integration: MD + MC analysis with cross-validation

**`bmad-technical-research`** - Research MM-GBSA best practices
- Focus: AMBERTools 23 integration, parameter optimization, error estimation
- Output: MM-GBSA protocol for MD and MC snapshots

### 8.2 Statistical Analysis

**`bmad-quick-dev`** - Implement statistical analysis pipeline
- Tests: Bonferroni correction, Cohen's d, 95% confidence intervals
- Correlations: Vina vs MD-MM-GBSA vs MC-MM-GBSA, RRS vs ΔΔG

**`bmad-review-adversarial-general`** - Critical review of analysis methods
- Focus: Statistical rigor, multiple testing correction, effect sizes
- Output: Validated analysis protocols meeting JCIM standards

---

## Phase 9: Manuscript Preparation (December 2026)

### 9.1 Content Creation

**`bmad-create-story`** - Create manuscript sections
- Sections: Methods, Results, Discussion, Supporting Information
- Focus: JCIM compliance, reproducibility, novel contributions

**`bmad-technical-research`** - Research JCIM submission requirements
- Requirements: Format, supplementary data, reproducibility standards
- Output: Submission checklist and formatting guidelines

### 9.2 Visualization & Figures

**`bmad-excalidraw`** - Create manuscript figures and diagrams
- Figures: ACSI plots, PNS networks, MD stability, MC landscapes
- Quality: Publication-ready with proper labeling and statistics

**`bmad-cis-storytelling`** - Craft compelling narrative
- Story: From Paper 1 limitations to MD validation to resistance insights
- Framework: Problem → Method → Results → Impact structure

### 9.3 Review & Refinement

**`bmad-editorial-review-prose`** - Review manuscript prose
- Focus: Clarity, conciseness, scientific accuracy, JCIM style
- Output: Polished manuscript ready for submission

**`bmad-editorial-review-structure`** - Review manuscript structure
- Focus: Logical flow, section organization, figure placement
- Output: Optimized manuscript structure

---

## Phase 10: Submission & Revision (January-March 2027)

### 10.1 Submission Preparation

**`bmad-check-implementation-readiness`** - Validate submission completeness
- Checklist: All figures, tables, supplementary data, code availability
- Compliance: JCIM requirements, reproducibility standards

**`bmad-review-adversarial-general`** - Pre-submission critical review
- Perspective: Anticipate reviewer concerns, strengthen weak points
- Output: Reviewer-ready manuscript with robust defense

### 10.2 Revision Management

**`bmad-correct-course`** - Manage revision process
- Tasks: Address reviewer comments, update analyses, revise text
- Coordination: Track changes, maintain version control

**`bmad-retrospective`** - Project retrospective and lessons learned
- Analysis: What worked well, what could be improved, future directions
- Output: Project completion summary and methodology refinements

---

## Continuous Skills (Throughout Project)

### Project Management

**`bmad-sprint-status`** - Monitor project progress
- Use: Weekly progress checks, milestone tracking
- Output: Status reports with risk identification

**`bmad-help`** - Navigate workflow decisions
- Use: When uncertain about next steps or skill selection
- Context: Phase transitions, problem-solving, prioritization

### Quality Assurance

**`bmad-code-review`** - Ongoing code quality maintenance
- Frequency: Before major milestones, after significant changes
- Focus: Scientific accuracy, reproducibility, maintainability

**`bmad-review-edge-case-hunter`** - Continuous edge case identification
- Application: All analysis scripts, data processing, validation steps
- Output: Robust, failure-resistant pipeline

### Documentation

**`bmad-document-project`** - Maintain project documentation
- Frequency: Monthly updates, major milestone documentation
- Content: Progress, decisions, methodology changes

**`bmad-index-docs`** - Organize project documentation
- Maintenance: Keep documentation discoverable and current
- Structure: Phase-based organization with cross-references

---

## Scientific Agent Skills (K-Dense)

Source: [scientific-agent-skills](https://github.com/K-Dense-AI/scientific-agent-skills) — 148 scientific skills for AI agents.

### Core MD/Chemistry Skills

**`molecular-dynamics`** — OpenMM + MDAnalysis simulation & trajectory analysis
- Use for: MC sampling implementation (OpenMM), trajectory analysis (MDAnalysis), force field setup
- Project 2: MC sampling script (`mc_sampling_openMM.py`), RMSD/RMSF/SASA analysis, MM-GBSA pipeline
- Covers: OpenMM System/Simulation, MDAnalysis universe, PBC handling, atom selection DSL

**`rdkit`** — Molecular property prediction, fingerprints, conformer generation
- Use for: ACSI calculation (Morgan fingerprints, Tanimoto distance), SMILES parsing, 3D conformer generation
- Project 2: ACSI `D_DrugBank` and `D_ANPDB` components, scaffold diversity check, Ro5 filtering
- Covers: AllChem, Descriptors, DataStructs, rdMolDescriptors, SanitizeMol

**`diffdock`** — Diffusion-based molecular docking
- Use for: DiffDock-L consensus docking, pose generation for MC starting structures
- Project 2: Dual-filter consensus with Vina, enrichment studies (DEKOIS 2.0)
- Covers: DiffDock inference, box configuration, pocket identification

**`networkx`** — Graph/network analysis for PPI networks
- Use for: PNS calculation (degree, betweenness, closeness, eigenvector centrality)
- Project 2: STRING PPI network analysis, composite centrality computation, network visualization
- Covers: centrality algorithms, graph construction, community detection, spring_layout

### Scientific Communication Skills

**`scientific-writing`** — Manuscript drafting, IMRAD structure, JCIM compliance
- Use for: Manuscript revision, Methods section reproducibility, Results section data presentation
- Project 2: v0.6→v0.7 manuscript updates, MC section writing, Limitations discussion
- Covers: Academic writing conventions, figure/table referencing, statistical reporting

**`peer-review`** — Critical manuscript evaluation, reviewer response
- Use for: Pre-submission internal review, anticipating reviewer concerns, response letters
- Project 2: Review before JCIM submission, address novelty/methodology/reproducibility concerns
- Covers: Strength/weakness identification, experimental design critique, statistical rigor

**`citation-management`** — Reference management, bibliography verification
- Use for: Fixing 14 fictitious .bib entries, CrossRef verification, DOI validation
- Project 2: `Bibliography_Paper2.bib` cleanup, verify `temgoua2026antimalarial` DOI status
- Covers: Zotero integration, BibTeX generation, citation style enforcement

### Data Analysis & Visualization Skills

**`scientific-visualization`** — Publication-quality figures with matplotlib/seaborn
- Use for: All 7 manuscript figures, supplementary heatmaps, network plots
- Project 2: ACSI distribution (F1), PPI network (F2), RMSD trajectories (F3), H-bond heatmap (F4), MC landscapes (F5), pose clusters (F6), cross-metric matrix (F7)
- Covers: Colorblind-safe palettes, journal formatting, multi-panel layouts

**`statistical-analysis`** — Hypothesis testing, correlation analysis, multiple testing correction
- Use for: Spearman correlations with Bonferroni correction, cross-metric hypothesis testing
- Project 2: H1 (ACSI↔RRS), H2 (PNS↔MM-GBSA), H3 (RRS↔ΔΔG) validation
- Covers: SciPy stats, permutation tests, effect sizes, confidence intervals

### Supplementary Skills

**`deepchem`** — Deep learning for molecular property prediction
- Use for: ADMET cross-validation, molecular property prediction comparison
- Project 2: Cross-validate ADMET-AI vs ADMETlab 3.0 vs SwissADME predictions

**`pymatgen`** — Materials/chemical structure analysis
- Use for: Crystal structure analysis, PDB structure manipulation (alternative to PyMOL)

**`medchem`** — Medicinal chemistry analysis, drug-likeness scoring
- Use for: QED calculation, scaffold analysis, lead-likeness assessment
- Project 2: QED component of MPO scoring

### Skill Integration Map by Phase

| Phase | Primary Skills | Supporting Skills |
|-------|---------------|-------------------|
| Phase 1 (Validation) | `citation-management`, `peer-review` | `statistical-analysis` |
| Phase 2 (Mutations) | `molecular-dynamics`, `rdkit` | `networkx` |
| Phase 3 (Metrics) | `rdkit`, `networkx`, `statistical-analysis` | `deepchem` |
| Phase 4 (Prep) | `molecular-dynamics`, `rdkit` | `diffdock` |
| Phase 5 (MD+MC) | `molecular-dynamics`, `diffdock` | `statistical-analysis` |
| Phase 6 (Analysis) | `molecular-dynamics`, `statistical-analysis` | `scientific-visualization` |
| Phase 7 (Manuscript) | `scientific-writing`, `scientific-visualization` | `citation-management`, `peer-review` |

---

## Success Metrics & Validation

### Technical Milestones
- [ ] 6 resistance mutant structures (QMEAN > -4.0, RMSD < 1.5 Å)
- [ ] 220 MD systems prepared and validated
- [ ] ≥80% systems pass stability criteria
- [ ] MC acceptance rates 20-40% for all systems
- [ ] |ΔG_MC - ΔG_MD| < 2 kcal/mol for ≥80% systems

### Scientific Deliverables
- [ ] RRS classification (Classes A-D) for top-20 candidates
- [ ] ACSI and PNS metrics validated and correlated
- [ ] MM-GBSA convergence (SE < 2 kcal/mol)
- [ ] ≥3 candidates show alternative binding modes in mutants

### Publication Readiness
- [ ] JCIM-compliant manuscript with all required sections
- [ ] Reproducible protocols with complete code availability
- [ ] Statistical rigor with appropriate corrections and effect sizes
- [ ] Novel contributions clearly articulated and validated

---

## Risk Mitigation Strategies

### Technical Risks
- **Homology model quality**: Use fallback methods (ColabFold → RoseTTAFold → PyMOL)
- **MD instability**: Report as results, identify failure patterns
- **MC convergence issues**: Extend sampling, adjust parameters
- **Resource constraints**: AWS cloud backup plan

### Scientific Risks
- **Weak correlations**: Investigate methodology, consider alternative metrics
- **Reviewer concerns**: Proactive validation, robust statistical analysis
- **Reproducibility issues**: Comprehensive documentation, version control

### Project Management Risks
- **Timeline delays**: Parallel processing, critical path optimization
- **Scope creep**: Regular sprint reviews, stakeholder alignment
- **Quality issues**: Continuous code review, automated testing

---

This skills roadmap provides a comprehensive framework for executing Project 2 using BMad methodology. Each phase builds systematically toward the final JCIM submission while maintaining scientific rigor and reproducibility standards.

---

## Specialized Agents for Enhanced Project 2 Execution

I've discovered several specialized agents that will significantly enhance your Project 2 work. Here's how each agent will contribute to your molecular dynamics validation project:

### **Mary (Business Analyst Agent)** - `bmad-agent-analyst`
**Purpose:** Strategic analysis and requirements elicitation for scientific projects

**Project 2 Applications:**
- **Domain Research (DR):** Deep dive into malaria resistance mechanisms, African epidemiology, and polypharmacology theory
- **Market Research (MR):** Analyze competitive landscape of antimalarial drug discovery, identify gaps in current approaches  
- **Technical Research (TR):** Research MD simulation best practices, Monte Carlo methodologies, and JCIM publication standards
- **Product Brief (CB):** Create comprehensive project briefs for each phase, ensuring alignment with JCIM requirements
- **Documentation (DP):** Analyze and document the complex Project 2 workflow for reproducibility

**How We'll Use Mary:**
- **Phase 1:** Research resistance mutation prevalence in African populations and competitive MD validation approaches
- **Phase 2:** Analyze JCIM publication requirements and develop strategic positioning for novel contributions
- **Phase 3:** Document domain expertise for novel metrics (RRS, ACSI, PNS) with biological rationale
- **Throughout:** Maintain strategic oversight, requirements clarity, and competitive intelligence

### **Winston (System Architect Agent)** - `bmad-agent-architect`
**Purpose:** Technical architecture and scalable system design

**Project 2 Applications:**
- **Create Architecture (CA):** Design the 220-system MD+MC pipeline architecture for scalability and reliability
- **Implementation Readiness (IR):** Ensure all components (protocols, scripts, analysis) are properly aligned and ready for production

**How We'll Use Winston:**
- **Phase 4:** Architect the MD system preparation pipeline for 220 systems with fault tolerance
- **Phase 5:** Design Monte Carlo integration with OpenMM and GROMACS workflows  
- **Phase 6:** Plan production simulation orchestration across 4 A100 GPUs (~45 days runtime)
- **Phase 7:** Architect analysis pipeline for trajectory and MC data processing (12 TB data)
- **Throughout:** Ensure technical decisions support reproducibility and JCIM standards

### **Amelia (Senior Developer Agent)** - `bmad-agent-dev`
**Purpose:** Precise code implementation following story specifications with comprehensive testing

**Project 2 Applications:**
- **Dev Story (DS):** Execute detailed implementation of MD pipeline components with 100% test coverage
- **Code Review (CR):** Multi-faceted code review ensuring scientific accuracy and robustness

**How We'll Use Amelia:**
- **Phase 3:** Implement refined homology modeling scripts with enhanced error handling and validation
- **Phase 4:** Develop novel metrics calculation (RRS, ACSI, PNS) with comprehensive validation
- **Phase 5:** Build ligand preparation pipeline with multiple force field support (CGenFF, OpenFF, GAFF2)
- **Phase 6:** Implement Monte Carlo sampling integration with OpenMM (10,000 steps per system)
- **Phase 7:** Create trajectory analysis and MM-GBSA calculation pipelines
- **Throughout:** Ensure all code meets scientific computing standards with comprehensive unit and integration tests

### **Quinn (QA Engineer Agent)** - `bmad-agent-qa`
**Purpose:** Rapid test generation and quality assurance for complex scientific pipelines

**Project 2 Applications:**
- **Generate E2E Tests (QA):** Create comprehensive end-to-end tests for the entire MD+MC pipeline

**How We'll Use Quinn:**
- **Phase 4:** Test homology modeling pipeline across all 6 resistance mutations with quality validation
- **Phase 5:** Validate ligand preparation for all force field combinations and edge cases
- **Phase 6:** Test Monte Carlo sampling convergence, acceptance rates (20-40%), and pose clustering
- **Phase 7:** Validate trajectory analysis, statistical calculations, and MM-GBSA convergence
- **Phase 8:** Test correlation analyses and ensure reproducibility of all reported results
- **Throughout:** Ensure pipeline robustness with realistic failure scenarios and recovery testing

### **Paige (Technical Writer Agent)** - `bmad-agent-tech-writer`
**Purpose:** Transform complex concepts into clear, structured documentation

**Project 2 Applications:**
- **Document Project (DP):** Generate comprehensive project documentation for reproducibility
- **Write Document (WD):** Author JCIM-compliant manuscript sections and protocols
- **Mermaid Diagrams (MG):** Create publication-quality workflow diagrams and figures
- **Explain Concepts (EC):** Develop clear explanations of novel methodologies for peer review

**How We'll Use Paige:**
- **Phase 1:** Document MD simulation protocols and Monte Carlo methodologies for reproducibility
- **Phase 4:** Create clear explanations of novel metrics (RRS, ACSI, PNS) with mathematical formulations
- **Phase 8:** Author Methods sections with step-by-step reproducible protocols meeting JCIM standards
- **Phase 9:** Generate publication-quality figures, workflow diagrams, and supplementary protocols
- **Phase 10:** Ensure JCIM compliance and develop reviewer-friendly explanations
- **Throughout:** Maintain comprehensive documentation enabling collaboration and reproducibility

---

## Enhanced Phase Integration with Specialized Agents

### **Phase 1-2: Strategic Foundation (May-June 2026)**
**Agent Team:** Mary (strategy) + Paige (documentation) + Winston (architecture)
- Mary researches domain expertise and competitive landscape
- Winston designs overall system architecture for 220 systems
- Paige documents foundational protocols and methodologies

### **Phase 3-4: Core Development (June 2026)**
**Agent Team:** Amelia (development) + Quinn (testing) + Mary (research)
- Mary provides domain expertise for resistance mutations and novel metrics
- Amelia implements homology modeling and metrics calculation with precision
- Quinn ensures comprehensive testing across all mutation types and edge cases

### **Phase 5-6: Pipeline Implementation (July-August 2026)**
**Agent Team:** Winston (architecture) + Amelia (development) + Quinn (validation)
- Winston architects the complex MD+MC pipeline for production scale
- Amelia implements system preparation and Monte Carlo integration
- Quinn validates pipeline robustness across all 220 system configurations

### **Phase 7-8: Production & Analysis (August-November 2026)**
**Agent Team:** All agents in coordinated effort
- Winston monitors production architecture and resource utilization
- Amelia implements analysis pipelines with statistical rigor
- Quinn validates all calculations and ensures reproducibility
- Mary provides strategic guidance on result interpretation
- Paige documents all methodologies for manuscript preparation

### **Phase 9-10: Publication (December 2026-March 2027)**
**Agent Team:** Paige (lead) + Mary (strategy) + Winston (validation)
- Paige leads manuscript development with JCIM compliance
- Mary ensures competitive positioning and addresses reviewer concerns
- Winston validates complete reproducibility package
- Quinn ensures all reported results are validated and reproducible

---

## Agent Integration Benefits for Project 2

### **Enhanced Scientific Rigor**
- **Mary's** domain expertise ensures biological relevance and competitive positioning
- **Winston's** architecture ensures scalability, reliability, and reproducibility
- **Amelia's** precision ensures implementation accuracy and comprehensive testing
- **Quinn's** testing ensures robustness across all scenarios and edge cases
- **Paige's** documentation ensures clarity, reproducibility, and JCIM compliance

### **Accelerated Development Timeline**
- Specialized agents work in parallel on different project aspects
- Each agent brings domain-specific best practices and expertise
- Reduced iteration cycles through expert guidance and early validation
- Comprehensive testing prevents late-stage failures and rework

### **JCIM Publication Success**
- **Mary** ensures competitive positioning, novelty, and strategic alignment
- **Winston** ensures technical soundness, scalability, and reproducibility
- **Amelia** ensures code quality, scientific accuracy, and comprehensive validation
- **Quinn** ensures robustness, edge case handling, and result reproducibility
- **Paige** ensures clear communication, JCIM compliance, and reviewer accessibility

### **Risk Mitigation Strategy**
- Multiple expert perspectives identify potential issues early in development
- Comprehensive testing prevents production failures and data loss
- Clear documentation enables effective collaboration and external review
- Strategic oversight maintains focus on key objectives and deliverables

---

## Recommended Agent Activation Sequence

### **Week 1-2: Foundation**
1. **Mary** - Domain and technical research for project foundation
2. **Winston** - Overall architecture design for 220-system pipeline
3. **Paige** - Initial protocol documentation and methodology explanations

### **Week 3-8: Core Development**
1. **Amelia** - Implement homology modeling and novel metrics with testing
2. **Quinn** - Comprehensive testing of all pipeline components
3. **Mary** - Ongoing research support and validation

### **Week 9-16: Production Pipeline**
1. **Winston** - Production architecture refinement and monitoring
2. **Amelia** - System preparation and Monte Carlo implementation
3. **Quinn** - Production validation and quality assurance

### **Week 17-32: Analysis & Manuscript**
1. **All agents** - Coordinated effort for analysis pipeline and manuscript
2. **Paige** - Lead manuscript development with agent support
3. **Mary** - Strategic guidance for publication and reviewer response

This enhanced approach leverages specialized agent expertise to ensure Project 2 success while maintaining the highest standards of scientific rigor and reproducibility required for JCIM publication.